Methylergonovine
As of the edition of 20 October 2026, Methylergonovine is a small molecule: marketed, first approved in 1950 (CH); acts on DRD1 and HTR2B.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1995
- Kind
- Small molecule
- Brand name
- Methergine
- First approved
- 1 April 1950 (CH)
- Approvals on record
- 5 in 4 regions
- Holder of the most recent approval
- ESSENTIAL PHARMA (M) (MALTE); 3 holders in all
- Registered trials
- 5, 1 stopped early
- Disease areas
- Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product2 company-target rows are on route B because of Methylergonovine.
See the 2 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 1 | 1 | 0 | 0 | 1 |
| Phase 4 | 3 | 3 | 0 | 0 |
| All trials | 5 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Essential Pharma | Applicant | 1950 to now |
| Edison Pharmaceuticals | Acquired holder | 2014 to now |
| Novartis | Applicant |